2w1d: Difference between revisions

From Proteopedia
Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:


==Structure determination of Aurora Kinase in complex with inhibitor==
==Structure determination of Aurora Kinase in complex with inhibitor==
<StructureSection load='2w1d' size='340' side='right' caption='[[2w1d]], [[Resolution|resolution]] 2.97&Aring;' scene=''>
<StructureSection load='2w1d' size='340' side='right'caption='[[2w1d]], [[Resolution|resolution]] 2.97&Aring;' scene=''>
== Structural highlights ==
== Structural highlights ==
<table><tr><td colspan='2'>[[2w1d]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2W1D OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2W1D FirstGlance]. <br>
<table><tr><td colspan='2'>[[2w1d]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2W1D OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=2W1D FirstGlance]. <br>
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=L0D:2-(1H-PYRAZOL-3-YL)-1H-BENZIMIDAZOLE'>L0D</scene></td></tr>
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=L0D:2-(1H-PYRAZOL-3-YL)-1H-BENZIMIDAZOLE'>L0D</scene></td></tr>
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[1muo|1muo]], [[2j50|2j50]], [[1ol7|1ol7]], [[1ol6|1ol6]], [[2bmc|2bmc]], [[2c6e|2c6e]], [[2j4z|2j4z]], [[1ol5|1ol5]], [[2c6d|2c6d]], [[1mq4|1mq4]], [[2w1g|2w1g]], [[2w1f|2w1f]], [[2w1i|2w1i]], [[2w1h|2w1h]], [[2w1e|2w1e]], [[2w1c|2w1c]]</td></tr>
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[1muo|1muo]], [[2j50|2j50]], [[1ol7|1ol7]], [[1ol6|1ol6]], [[2bmc|2bmc]], [[2c6e|2c6e]], [[2j4z|2j4z]], [[1ol5|1ol5]], [[2c6d|2c6d]], [[1mq4|1mq4]], [[2w1g|2w1g]], [[2w1f|2w1f]], [[2w1i|2w1i]], [[2w1h|2w1h]], [[2w1e|2w1e]], [[2w1c|2w1c]]</td></tr>
<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Non-specific_serine/threonine_protein_kinase Non-specific serine/threonine protein kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.11.1 2.7.11.1] </span></td></tr>
<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Non-specific_serine/threonine_protein_kinase Non-specific serine/threonine protein kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.11.1 2.7.11.1] </span></td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2w1d FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2w1d OCA], [http://pdbe.org/2w1d PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=2w1d RCSB], [http://www.ebi.ac.uk/pdbsum/2w1d PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=2w1d ProSAT]</span></td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=2w1d FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2w1d OCA], [http://pdbe.org/2w1d PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=2w1d RCSB], [http://www.ebi.ac.uk/pdbsum/2w1d PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=2w1d ProSAT]</span></td></tr>
</table>
</table>
== Evolutionary Conservation ==
== Evolutionary Conservation ==
Line 30: Line 30:


==See Also==
==See Also==
*[[Serine/threonine protein kinase|Serine/threonine protein kinase]]
*[[Serine/threonine protein kinase 3D structures|Serine/threonine protein kinase 3D structures]]
== References ==
== References ==
<references/>
<references/>
Line 36: Line 36:
</StructureSection>
</StructureSection>
[[Category: Human]]
[[Category: Human]]
[[Category: Large Structures]]
[[Category: Non-specific serine/threonine protein kinase]]
[[Category: Non-specific serine/threonine protein kinase]]
[[Category: Berdini, V]]
[[Category: Berdini, V]]

Revision as of 11:46, 25 June 2020

Structure determination of Aurora Kinase in complex with inhibitorStructure determination of Aurora Kinase in complex with inhibitor

Structural highlights

2w1d is a 1 chain structure with sequence from Human. Full crystallographic information is available from OCA. For a guided tour on the structure components use FirstGlance.
Ligands:
Activity:Non-specific serine/threonine protein kinase, with EC number 2.7.11.1
Resources:FirstGlance, OCA, PDBe, RCSB, PDBsum, ProSAT

Evolutionary Conservation

Check, as determined by ConSurfDB. You may read the explanation of the method and the full data available from ConSurf.

Publication Abstract from PubMed

Here, we describe the identification of a clinical candidate via structure-based optimization of a ligand efficient pyrazole-benzimidazole fragment. Aurora kinases play a key role in the regulation of mitosis and in recent years have become attractive targets for the treatment of cancer. X-ray crystallographic structures were generated using a novel soakable form of Aurora A and were used to drive the optimization toward potent (IC(50) approximately 3 nM) dual Aurora A/Aurora B inhibitors. These compounds inhibited growth and survival of HCT116 cells and produced the polyploid cellular phenotype typically associated with Aurora B kinase inhibition. Optimization of cellular activity and physicochemical properties ultimately led to the identification of compound 16 (AT9283). In addition to Aurora A and Aurora B, compound 16 was also found to inhibit a number of other kinases including JAK2 and Abl (T315I). This compound demonstrated in vivo efficacy in mouse xenograft models and is currently under evaluation in phase I clinical trials.

Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity.,Howard S, Berdini V, Boulstridge JA, Carr MG, Cross DM, Curry J, Devine LA, Early TR, Fazal L, Gill AL, Heathcote M, Maman S, Matthews JE, McMenamin RL, Navarro EF, O'Brien MA, O'Reilly M, Rees DC, Reule M, Tisi D, Williams G, Vinkovic M, Wyatt PG J Med Chem. 2009 Jan 22;52(2):379-88. PMID:19143567[1]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

See Also

References

  1. Howard S, Berdini V, Boulstridge JA, Carr MG, Cross DM, Curry J, Devine LA, Early TR, Fazal L, Gill AL, Heathcote M, Maman S, Matthews JE, McMenamin RL, Navarro EF, O'Brien MA, O'Reilly M, Rees DC, Reule M, Tisi D, Williams G, Vinkovic M, Wyatt PG. Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. J Med Chem. 2009 Jan 22;52(2):379-88. PMID:19143567 doi:10.1021/jm800984v

2w1d, resolution 2.97Å

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA